Cullinan Associates’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.56M Sell
42,219
-8,775
-17% -$512K 0.21% 82
2025
Q4
$2.75M Sell
50,994
-4,625
-8% -$222K 0.19% 92
2025
Q3
$2.51M Sell
55,619
-10,312
-16% -$482K 0.16% 97
2025
Q2
$3.05M Sell
65,931
-3,989
-6% -$196K 0.2% 87
2025
Q1
$4.26M Sell
69,920
-1,684
-2% -$98.2K 0.3% 71
2024
Q4
$4.05M Sell
71,604
-20,628
-22% -$1.15M 0.26% 76
2024
Q3
$4.82M Sell
92,232
-13,324
-13% -$625K 0.27% 76
2024
Q2
$4.38M Sell
105,556
-3,782
-3% -$169K 0.25% 80
2024
Q1
$5.93M Sell
109,338
-4,946
-4% -$252K 0.33% 62
2023
Q4
$5.86M Sell
114,284
-26,085
-19% -$1.37M 0.33% 70
2023
Q3
$8.15M Buy
140,369
+5,986
+4% +$367K 0.47% 52
2023
Q2
$8.59M Sell
134,383
-29,439
-18% -$1.97M 0.47% 59
2023
Q1
$11.4M Buy
163,822
+38,134
+30% +$2.69M 0.66% 43
2022
Q4
$9.04M Buy
125,688
+14,710
+13% +$1.11M 0.5% 46
2022
Q3
$7.89M Buy
110,978
+11,713
+12% +$850K 0.5% 54
2022
Q2
$7.64M Sell
99,265
-2,457
-2% -$187K 0.47% 60
2022
Q1
$7.43M Sell
101,722
-175,510
-63% -$11.8M 0.39% 72
2021
Q4
$17.3M Buy
277,232
+2,200
+0.8% +$129K 0.88% 30
2021
Q3
$16.3M Buy
275,032
+7,265
+3% +$478K 0.9% 29
2021
Q2
$17.9M Buy
267,767
+15,534
+6% +$1.01M 1% 20
2021
Q1
$15.9M Buy
252,233
+381
+0.2% +$23.7K 0.92% 19
2020
Q4
$15.6M Sell
251,852
-13,057
-5% -$803K 0.94% 18
2020
Q3
$16M Sell
264,909
-9,030
-3% -$543K 1.03% 15
2020
Q2
$16.1M Buy
273,939
+645
+0.2% +$38.6K 1.13% 13
2020
Q1
$15.2M Sell
273,294
-2,684
-1% -$164K 1.25% 12
2019
Q4
$17.7M Buy
275,978
+7,794
+3% +$446K 1.18% 16
2019
Q3
$13.6M Buy
268,184
+77,126
+40% +$3.62M 0.97% 18
2019
Q2
$8.66M Buy
191,058
+58,901
+45% +$2.74M 0.63% 46
2019
Q1
$6.3M Buy
132,157
+54,907
+71% +$2.74M 0.47% 59
2018
Q4
$4.01M Sell
77,250
-4,150
-5% -$223K 0.33% 79
2018
Q3
$5.05M Sell
81,400
-6,300
-7% -$374K 0.37% 77
2018
Q2
$4.85M Sell
87,700
-30,500
-26% -$1.65M 0.37% 77
2018
Q1
$7.48M Sell
118,200
-3,496
-3% -$225K 0.57% 41
2017
Q4
$7.46M Sell
121,696
-6,500
-5% -$407K 0.55% 44
2017
Q3
$8.17M Sell
128,196
-4,050
-3% -$236K 0.63% 43
2017
Q2
$7.37M Sell
132,246
-2,250
-2% -$122K 0.57% 47
2017
Q1
$7.31M Buy
134,496
+3,628
+3% +$199K 0.6% 49
2016
Q4
$7.65M Buy
130,868
+41,772
+47% +$2.28M 0.65% 41
2016
Q3
$4.8M Sell
89,096
-496,700
-85% -$31.9M 0.41% 70
2016
Q2
$43.1M Buy
585,796
+88,700
+18% +$6.27M 3.5% 4
2016
Q1
$31.8M Sell
497,096
-503,200
-50% -$31.7M 2.71% 4
2015
Q4
$68.8M Buy
1,000,296
+5,840
+0.6% +$386K 5.99% 2
2015
Q3
$58.9M Sell
994,456
-333,405
-25% -$21.2M 5.38% 2
2015
Q2
$88.4M Sell
1,327,861
-26,940
-2% -$1.78M 7.29% 2
2015
Q1
$87.4M Sell
1,354,801
-30,510
-2% -$1.91M 6.78% 2
2014
Q4
$81.8M Buy
1,385,311
+323,008
+30% +$18.2M 8.66% 2
2014
Q3
$54.4M Buy
1,062,303
+980,565
+1,200% +$49M 6.19% 4
2014
Q2
$3.65M Sell
81,738
-881,455
-92% -$43.4M 0.59% 27
2014
Q1
$50M Sell
963,193
-60,345
-6% -$3.21M 5.69% 5
2013
Q4
$54.4M Buy
1,023,538
+891,300
+674% +$45.4M 6.31% 5
2013
Q3
$6.12M Buy
132,238
+15,750
+14% +$691K 0.82% 22
2013
Q2
$5.21M Buy
+116,488
New +$5.06M 0.7% 24

Other funds holding BMY

Cullinan Associates's BMY Position: Q1 2026 in Review

Cullinan Associates reduced its Bristol-Myers Squibb (BMY) stake by 17% in Q1 2026, selling an estimated $512K and leaving 42,219 shares worth $2.56M. The position accounts for 0.21% of the portfolio, ranked #82.

Cullinan Associates first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $88.4M in Q2 2015. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Cullinan Associates held 42,219 shares of Bristol-Myers Squibb worth $2.56M as of Q1 2026.
  • Cullinan Associates sold 8,775 Bristol-Myers Squibb shares in Q1 2026, an estimated $512K.
  • Bristol-Myers Squibb made up 0.21% of Cullinan Associates's portfolio in Q1 2026, its #82 holding.
  • Cullinan Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Cullinan Associates's Bristol-Myers Squibb position peaked at $88.4M in Q2 2015.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Cullinan Associates's 13F filing for Q1 2026, filed 1 May 2026.